IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
June 25 2024 - 9:00AM
Business Wire
- Mouse Studies Demonstrate Significant
Reduction in Amyloid Plaque: 78% in Cortex and 85% in Hippocampus
-
IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company")
today announced encouraging preclinical results in an Alzheimer’s
mouse model demonstrating the potential of the Company’s
therapeutic candidate, TGR-63, to combat Alzheimer's disease.
“These preclinical results for TGR-63 are highly encouraging.
The significant reduction in amyloid plaque burden in an
Alzheimer’s mouse model observed in this study suggests TGR-63 has
the potential to be a transformative treatment for Alzheimer's
disease. TGR-63 is filed for patent protection in U.S. patent
application (USPTO Patent Application Number: 18/006,578), further
strengthening its potential value. We are committed to advancing
TGR-63 through clinical trials to determine its efficacy and safety
in human patients, offering new hope for the 50 million individuals
affected by this devastating illness," said Ram Mukunda, CEO of IGC
Pharma.
Alzheimer's disease is characterized by the buildup of abnormal
protein aggregates in the brain, including amyloid plaques. These
plaques are thought to play a major role in the cognitive decline
and memory loss associated with the disease. Current medications
for Alzheimer's primarily focus on reducing or clearing amyloid
plaque, highlighting its importance as a therapeutic target.
In a mouse model of Alzheimer's, TGR-63 treatment led to a
substantial reduction of amyloid plaque. Compared to untreated
mice, TGR-63 treatment reduced plaque deposits by 78% in the
cortex, a critical brain region for memory and cognition, and by
85% in the hippocampus, which plays a central role in learning and
memory. These findings suggest TGR-63's potential to slow or even
reverse the progression of Alzheimer's disease.
Prior to in vivo studies, TGR-63 demonstrated its ability to
disrupt the formation of toxic amyloid beta (Aβ42) aggregates in
cell cultures and increase the viability of neuronal cells exposed
to Aβ42, indicating potential neuroprotective effects. TGR-63's
unique structure allows it to interact with amyloid beta
aggregates, potentially disrupting their structure and promoting
their breakdown or clearance by the body's natural waste disposal
systems. This could ultimately lead to a reduction in plaque burden
in the brain, although there can be no assurance. The positive
results from these preclinical studies could pave the way for
advancing TGR-63 through clinical trials. IGC Pharma expects to
begin a Phase 1 trial for TGR-63 in 2025, although there can be no
assurance.
About IGC Pharma, Inc.
IGC Pharma (“IGC”) is focused on Alzheimer’s disease, developing
innovative therapies to address this devastating illness. The
Company’s mission is to transform the landscape of Alzheimer’s
treatment with a robust pipeline of five promising drug candidates.
IGC-AD1 is currently undergoing a Phase 2 clinical trial for
agitation in dementia associated with Alzheimer’s
(clinicaltrials.gov, NCT05543681).
The remaining four molecules are in the pre-clinical stage of
development. TGR-63 disrupts the progression of Alzheimer’s by
targeting Aβ plaques, a key hallmark of Alzheimer’s. IGC-1C,
targets tau protein and neurofibrillary tangles, representing a
forward-thinking approach to Alzheimer’s therapy. IGC-M3, aims to
inhibit the aggregation of Aβ plaques, potentially impacting
early-stage Alzheimer’s. LMP is designed to target multiple
hallmarks of Alzheimer’s including plaques and tangles for a
comprehensive approach to the disease. In addition to our drug
development pipeline, we are harnessing the power of Artificial
Intelligence to develop early disease detection models, optimize
our clinical trials, and explore new applications for our
drugs.
Forward-looking
Statements
This press release contains forward-looking statements. These
forward-looking statements are based largely on IGC Pharma’s
expectations and are subject to several risks and uncertainties,
certain of which are beyond IGC Pharma’s control. Actual results
could differ materially from these forward-looking statements as a
result of, among other factors, the Company’s failure or inability
to commercialize one or more of the Company’s products or
technologies, including the products or formulations described in
this release, or failure to obtain regulatory approval for the
products or formulations, where required, or government regulations
affecting AI or the AI algorithms not working as intended or
producing accurate predictions; general economic conditions that
are less favorable than expected; the FDA’s general position
regarding cannabis- and hemp-based products; and other factors,
many of which are discussed in IGC Pharma’s U.S. Securities and
Exchange Commission (“SEC”) filings. IGC Pharma incorporates by
reference the human trial disclosures and Risk Factors identified
in its Annual Report on Form 10-K filed with the SEC on July 24,
2024, as if fully incorporated and restated herein. Considering
these risks and uncertainties, there can be no assurance that the
forward-looking information contained in this release will
occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625363805/en/
Investors IMS Investor Relations Walter Frank/Rosalyn
Christian igc@imsinvestorrelations.com (203) 972-9200
Media JVPRNY Janet Vasquez jvasquez@jvprny.com (212)
645-5498
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Aug 2023 to Aug 2024